- Home
- DXR vs SRZN Comparison
DXR vs SRZN Comparison
Compare DXR & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- SRZN
- Stock Information
- Founded
- DXR 1970
- SRZN 2015
- Country
- DXR United States
- SRZN United States
- Employees
- DXR N/A
- SRZN N/A
- Industry
- DXR Medical/Dental Instruments
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- DXR Health Care
- SRZN Health Care
- Exchange
- DXR Nasdaq
- SRZN Nasdaq
- Market Cap
- DXR 42.6M
- SRZN 38.1M
- IPO Year
- DXR N/A
- SRZN N/A
- Fundamental
- Price
- DXR $8.24
- SRZN $10.57
- Analyst Decision
- DXR Strong Buy
- SRZN
- Analyst Count
- DXR 1
- SRZN 0
- Target Price
- DXR $24.75
- SRZN N/A
- AVG Volume (30 Days)
- DXR 23.0K
- SRZN 49.1K
- Earning Date
- DXR 01-01-0001
- SRZN 11-06-2024
- Dividend Yield
- DXR N/A
- SRZN N/A
- EPS Growth
- DXR N/A
- SRZN N/A
- EPS
- DXR 0.35
- SRZN N/A
- Revenue
- DXR $154,205.00
- SRZN $10,000,000.00
- Revenue This Year
- DXR N/A
- SRZN N/A
- Revenue Next Year
- DXR N/A
- SRZN N/A
- P/E Ratio
- DXR $23.96
- SRZN N/A
- Revenue Growth
- DXR N/A
- SRZN N/A
- 52 Week Low
- DXR $7.19
- SRZN $6.00
- 52 Week High
- DXR $10.04
- SRZN $16.19
- Technical
- Relative Strength Index (RSI)
- DXR 40.06
- SRZN 54.47
- Support Level
- DXR $8.04
- SRZN $9.50
- Resistance Level
- DXR $8.42
- SRZN $11.27
- Average True Range (ATR)
- DXR 0.36
- SRZN 1.10
- MACD
- DXR -0.09
- SRZN 0.01
- Stochastic Oscillator
- DXR 14.47
- SRZN 41.36
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).